Nisa Investment Advisors LLC Has $177,000 Position in NeoGenomics, Inc. (NASDAQ:NEO)

Nisa Investment Advisors LLC lowered its holdings in NeoGenomics, Inc. (NASDAQ:NEO) by 56.7% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 18,698 shares of the medical research company’s stock after selling 24,517 shares during the period. Nisa Investment Advisors LLC’s holdings in NeoGenomics were worth $177,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of the business. Sterling Capital Management LLC increased its position in shares of NeoGenomics by 788.7% during the fourth quarter. Sterling Capital Management LLC now owns 3,706 shares of the medical research company’s stock worth $61,000 after buying an additional 3,289 shares during the period. Teacher Retirement System of Texas bought a new stake in NeoGenomics in the first quarter worth about $178,000. Sherbrooke Park Advisers LLC purchased a new position in shares of NeoGenomics in the fourth quarter worth about $183,000. Cibc World Markets Corp purchased a new position in shares of NeoGenomics in the fourth quarter worth about $197,000. Finally, Summit Investment Advisors Inc. grew its stake in NeoGenomics by 6.9% in the 4th quarter. Summit Investment Advisors Inc. now owns 13,339 shares of the medical research company’s stock worth $220,000 after buying an additional 863 shares in the last quarter. Institutional investors own 98.50% of the company’s stock.

Insider Activity at NeoGenomics

In related news, Director Lynn A. Tetrault acquired 7,000 shares of NeoGenomics stock in a transaction dated Friday, May 9th. The shares were acquired at an average cost of $8.14 per share, for a total transaction of $56,980.00. Following the completion of the transaction, the director directly owned 7,000 shares of the company’s stock, valued at $56,980. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, COO Warren Stone purchased 5,700 shares of the company’s stock in a transaction on Monday, May 12th. The shares were purchased at an average price of $8.58 per share, with a total value of $48,906.00. Following the completion of the purchase, the chief operating officer directly owned 108,280 shares of the company’s stock, valued at $929,042.40. The trade was a 5.56% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders bought 70,600 shares of company stock valued at $550,438 in the last 90 days. 2.40% of the stock is owned by corporate insiders.

NeoGenomics Stock Performance

Shares of NEO opened at $6.72 on Friday. The stock has a 50-day simple moving average of $7.43 and a 200-day simple moving average of $10.11. The company has a debt-to-equity ratio of 0.38, a quick ratio of 1.95 and a current ratio of 2.05. The stock has a market capitalization of $864.86 million, a PE ratio of -11.02 and a beta of 1.63. NeoGenomics, Inc. has a 1 year low of $6.08 and a 1 year high of $19.12.

NeoGenomics (NASDAQ:NEO) last released its quarterly earnings results on Tuesday, April 29th. The medical research company reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.02) by ($0.06). The firm had revenue of $168.04 million for the quarter, compared to analyst estimates of $171.38 million. NeoGenomics had a negative return on equity of 2.21% and a negative net margin of 11.54%. The company’s quarterly revenue was up 7.6% on a year-over-year basis. During the same period last year, the firm earned ($0.02) EPS. On average, analysts predict that NeoGenomics, Inc. will post -0.2 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the stock. The Goldman Sachs Group lowered their price target on shares of NeoGenomics from $15.00 to $10.00 and set a “buy” rating for the company in a report on Wednesday, April 30th. Needham & Company LLC dropped their price objective on shares of NeoGenomics from $18.00 to $8.50 and set a “buy” rating on the stock in a report on Tuesday, April 29th. Morgan Stanley decreased their target price on shares of NeoGenomics from $17.00 to $10.00 and set an “equal weight” rating on the stock in a research note on Thursday, May 1st. Leerink Partnrs lowered shares of NeoGenomics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, April 30th. Finally, Piper Sandler set a $12.00 price objective on shares of NeoGenomics and gave the stock an “overweight” rating in a research note on Tuesday, May 6th. Seven research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, NeoGenomics currently has an average rating of “Hold” and a consensus price target of $13.83.

About NeoGenomics

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.